DEINOVE annonce l’avis favorable du DSMB pour la poursuite de l’essai clinique de Phase II de DNV3837 dans les infections à Clostridioïdes difficile
January 06, 2022 11:45 ET
|
Deinove
DEINOVE annonce l’avis favorable du DSMB pour la poursuite de l’essai clinique de Phase II de DNV3837 dans les infections à Clostridioïdes difficile Le DSMB1 a jugé que la balance bénéfice/risque de...
DEINOVE announces a favorable opinion from the DSMB for the continuation of the Phase II clinical trial of DNV3837 in Clostridioides difficile infections
January 06, 2022 11:45 ET
|
Deinove
DEINOVE announces a favorable opinion from the DSMB for the continuation of the Phase II clinical trial of DNV3837 in Clostridioides difficile infections The DSMB1 considered that the benefit/risk...
uniQure Announces Latest Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
November 02, 2021 07:05 ET
|
uniQure Inc.
~ No Significant Safety Concerns Observed in First Four Patients Enrolled in Higher-dose Cohort ~ ~ Enrollment Expected to be Completed by Mid-2022 ~ LEXINGTON, Mass. and AMSTERDAM, Nov. 02,...
Immunicum tillkännager positiv granskning från Data Safety Monitoring Board av fas Ib IILIAD-studien
July 26, 2021 02:00 ET
|
Immunicum AB
Press Release 26 July 2021 Immunicum tillkännager positiv granskning från Data Safety Monitoring Board av fas Ib IILIAD-studien -- Independent Data Safety and Monitoring Board (DSMB) har avgivit...
Immunicum Announces Positive Review by Data Safety Monitoring Board for Phase Ib Part of ILIAD Study
July 26, 2021 02:00 ET
|
Immunicum AB
Press Release 26 July 2021 Immunicum Announces Positive Review by Data Safety Monitoring Board for Phase Ib Part of ILIAD Study -- Independent Data Safety and Monitoring Board (DSMB) issues...
HIV Cure Program Releases Initial Clinical Trial Data
July 15, 2021 23:51 ET
|
American Gene Technologies
ROCKVILLE, Md., July 15, 2021 (GLOBE NEWSWIRE) -- American Gene Technologies (AGT) announced today that the Data and Safety Monitoring Board (DSMB) voted unanimously to continue AGT’s HIV cure...
uniQure Announces Positive Recommendation to Advance Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
May 27, 2021 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, May 27, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces Positive Recommendation from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
February 08, 2021 07:05 ET
|
uniQure Inc.
~ No Significant Safety Concerns Observed ~ ~ Independent Data Safety Monitoring Board Recommends Proceeding with Study Enrollment ~ ~ Full Enrollment of First Cohort Expected Mid-2021 ~ LEXINGTON,...
BioAegis Therapeutics Expands Phase 2 COVID-19 Treatment Clinical Trial in EU for Inflammation Regulator
November 15, 2020 19:35 ET
|
BioAegis Therapeutics
No drug-related safety signals identified by the independent Data and Safety Monitoring Board.MORRISTOWN, N.J., Nov. 15, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage,...
Celsion Reports Data Safety Monitoring Board Recommendation to Proceed to Phase II of the OVATION 2 Study in Advanced Ovarian Cancer
May 29, 2020 08:30 ET
|
Celsion CORP
Excellent Surgical Response Noted at the Higher, 100 mg/m2 Dose Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit When Administered Over a Six-Month...